Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06430424
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-25
First Post:
2024-03-27
Brief Title:
Study of Metabolic Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Study of Metabolic Genomic and Proteomic Modifications in Relapsed Glioblastoma Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GBrecurr
Brief Summary:
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy STUPP protocol The aim of this study is to better characterize transcriptomic proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor in order to identify new prognostic markers and potential new therapeutic targets
Detailed Description:
Glioblastomas are the most frequent and aggressive malignant Central Nervous System CNS tumors in adults with a median survival of only 14 months
Current treatment is based on surgery followed by radiochemotherapy STUPP protocol unchanged since 2005 Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant
The aim of this retrospective study is to investigate the transcriptomic proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux France between 2005 and 2023 for which tumor material is available These analyses will be correlated with relapse-free and overall survival of the patients
Current treatment is based on surgery followed by radiochemotherapy STUPP protocol unchanged since 2005 Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant
The aim of this retrospective study is to investigate the transcriptomic proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux France between 2005 and 2023 for which tumor material is available These analyses will be correlated with relapse-free and overall survival of the patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None